LKFT today
$33.98+$0.05 (+0.15%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourLeaning Bullish
15 minBullish
5 minStrong Bullish
Daily trend turns down below $31.90
Key levels
Resistance$36.24
Resistance$34.49
Support$33.40
Support$32.27
Latest news & SEC filings
EarningsLakefront Biotherapeutics posts smaller quarterly loss than expected, revenue falls short
All LKFT news →About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a Belgian biotechnology company developing medicines for serious diseases. Its clinical pipeline centers on GLPG3667, an oral TYK2 inhibitor being studied in dermatomyositis and lupus, while its cell therapy programs in lymphoma and multiple myeloma are being wound down. The company operates mainly from Mechelen, Belgium, with additional offices in Chicago and San Francisco, and pursues oncology and immunology programs through business development deals.
Based on the company's 20-F filed Mar 26, 2026.
Nasdaq · Healthcare
Lakefront Biotherapeutics NV (LKFT)
What Is the Price Target for LKFT?
SEPT Low Target
$26.00
SEPT Mid Target
$35.50
SEPT High Target
$45.00
Analyst Consensus
$35.50
Is LKFT a Buy or Sell Right Now?
Thesis
- •Revenue growing 320.9% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LKFT.
Start Free Trial →Is LKFT Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
Analyst Consensus
Fair Value
$35.50
54
Moat Score
NARROW
6/9
Piotroski Score
8.3
Altman Z-Score
What Is Smart Money Doing with LKFT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LKFT Growth Story
Revenue YoY
320.9%
3yr Revenue CAGR
70.4%
EPS Growth YoY
353.61%
FCF Growth YoY
16.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for LKFT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LKFT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:17:48 | $33.78 | 1,200 | $$41K | MIDPOINT |
| 20:57:46 | $33.97 | 1,400 | $$48K | MIDPOINT |
| 20:48:00 | $33.87 | 1,000 | $$34K | BUY |
| 19:57:48 | $33.78 | 1,000 | $$34K | MIDPOINT |
| 15:39:58 | $35.25 | 22,398 | $$790K | MIDPOINT |
5 dark pool trades shown · $$945K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Lakefront Biotherapeutics NV (LKFT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LKFT — frequently asked questions
What is LKFT stock price today?
Lakefront Biotherapeutics NV (LKFT) is at $33.98, up 0.15% (+$0.05) at the Nov 13, 2026 close.
Why is LKFT stock moving today?
Latest LKFT news — Nov 11, 2026: Lakefront Biotherapeutics posts smaller quarterly loss than expected, revenue falls short
What is the LKFT price target?
The average analyst price target for LKFT is $35.50, ranging from $26 to $45, based on 2 analysts. Latest: RBC Capital upgrade on Sep 23, 2026.
What do analysts rate LKFT?
Analyst ratings for LKFT: 1 Buy, 2 Hold, 0 Sell — consensus Hold.
Did LKFT beat earnings?
LKFT last reported on Aug 10, 2026: EPS $0.03 vs -$0.82 expected — a beat of 104.2%.
What are LKFT support and resistance levels?
Support: $33.40, $32.27, $31.27. Resistance: $34.49, $36.24, $37.19.
What are insiders doing with LKFT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on LKFT?
Nov 11, 2026: Lakefront Biotherapeutics posts smaller quarterly loss than expected, revenue falls short